Acute myeloid leukemia: 2019 update on risk-stratification and management
Acute myeloid leukemia: 2019 update on risk-stratification and management
复制标题
DOI：
10.1002/ajh.25214
复制
发表时间：
2018-10-01
影响因子：
12.8
通讯作者：
Estey, Elihu H.
中科院分区：
文献类型：
--
作者：
Estey, Elihu H.
急性髓性白血病（AML）患者的结局范围从开始治疗后几天内死亡（治疗相关死亡率，TRM）到可能治愈。患者未治愈的主要原因是对治疗的抵抗，通常表现为缓解后复发，而不是TRM，即使在老年患者中，TRM的发病率也在下降。对治疗前各种基因突变状态的了解提高了我们分配初始治疗的能力，特别重要的是，对表面缓解的患者是否有可测量的残留疾病的了解应影响后续管理。FDA已经批准了几种新药，我们讨论它们在治疗中的作用。
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason patients are not cured is resistance to treatment, often manifested as relapse from remission, rather than, even in older patients, TRM, whose incidence is decreasing. Knowledge of the pre-treatment mutation status of various genes has improved our ability to assign initial treatment and, of particular importance, knowledge of whether patients ostensibly in remission have measurable residual disease should influence subsequent management. Several new drugs have been approved by the FDA and we discuss their role in treatment.